Anthranilic Acid–G-Protein Coupled Receptor109A–Cytosolic Phospholipase A2–Myelin–Cognition Cascade: A New Target for the Treatment/Prevention of Cognitive Impairment in Schizophrenia, Dementia, and Aging
Gregory Oxenkrug, José Marco-Contelles · 2024
Read Anthranilic Acid–G-Protein Coupled Receptor109A–Cytosolic Phospholipase A2–Myelin–Cognition Cascade: A New Target for the Treatment/Prevention of Cognitive Impairment in Schizophrenia, Dementia, and Aging by Gregory Oxenkrug, José Marco-Contelles (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11675959.txt.
Description
Gregory Oxenkrug and José Marco-Contelles lay out in 2024 a proposed chain of biology that could become a new drug target for failing memory and thinking. Such impairment sits at the core of schizophrenia and of aging-related diseases like Alzheimer's dementia, and current drugs help only a little.
Their review links anthranilic acid to a receptor called GPR109A, then to an enzyme that frees fatty acids, and from there to myelin, the fatty sheath that speeds nerve signals. Damage to that sheath may come early in dementia, before amyloid plaques build up. The authors argue the whole chain deserves testing as a route to prevention and treatment.
Catalog record
| CREATOR | Gregory Oxenkrug, José Marco-Contelles |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |